COMP <GO>
AGIO vs PRGO // PIOTROSKI F-SCORE QUALITY
Agios Pharmaceuticals Inc. (NASDAQ) VS. Perrigo Company plc (NYSE) • 15-METRIC TALLY: AGIO 4
— PRGO 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: PRGO
LAST: $37.23 (-2.33%) • MKT CAP: $2.22B
piotroski-score
4/9
LAST: $15.90 (-0.13%) • MKT CAP: $2.21B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. PRGO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGIO | PRGO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.30% | 35.10% | +53.20 | AGIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.80% | -13.60% | -20.20 | PRGO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.97% | 6.58% | -23.55 | PRGO | /fcf-yield <GO> |
| Operating Margin | -60.00% | -26.40% | -33.60 | PRGO | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -33.50% | -26.50 | PRGO | /net-margins <GO> |
| Revenue Growth (YoY) | 48.00% | -2.80% | +50.80 | AGIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 7.22% | -7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.84 | 0.20 | +11.64 | AGIO | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 5/9 | -1.00 | PRGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 56.7 | -0.10 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.22B | $2.21B | $16.3M | AGIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGIO REV | PRGO REV | AGIO GROSS % | PRGO GROSS % | AGIO FCF | PRGO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $54.0M | $4.25B | 88.3% | 35.1% | -$377.3M | $145.1M |
| FY 2024 | $36.5M | $4.37B | 88.6% | 35.3% | -$391.5M | $244.6M |
| FY 2023 | $26.8M | $4.66B | — | — | -$296.1M | $405.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
PRGO // BETA —